Every 8-K that Ultralife Corporation (ULBI) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow ULBI and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full ULBI filings page.
Ultralife Corporation reported second quarter 2026 revenue of $47.9 million, down 1.3% from a year ago, as Battery & Energy Products sales decreased 3.7% to $44.2 million while Communications Systems sales grew 39.3% to $3.8 million. Total backlog exited the quarter at a record $117.5 million, up from $84.5 million a year earlier.
Gross profit increased to $13.9 million, with gross margin expanding to 28.9% and delivering a 760-basis point improvement versus the first quarter, driven by manufacturing initiatives, favorable mix and an IEEPA tariff refund. Operating income rose to $3.4 million and net income attributable to Ultralife grew to $2.5 million, or $0.15 per share, compared with $0.9 million, or $0.05 per share, last year. Adjusted EBITDA was $6.1 million, or 12.8% of sales, versus $4.1 million, or 8.5% of sales, reflecting higher profitability despite increased R&D spending and $0.9 million of one-time litigation and consulting costs.
Ultralife Corporation held its 2026 Annual Meeting of Stockholders on July 22, 2026. Stockholders of record on May 28, 2026, owning 16,656,669 shares of common stock, were eligible to vote; 13,980,794 shares, or 83.93%, were present in person or by proxy, constituting a quorum.
All five nominees were elected to the Board of Directors, each receiving more than 10.2 million votes in favor, with 2,700,325 broker non-votes recorded for each director. Stockholders ratified WithumSmith+Brown, PC as independent registered public accounting firm for 2026 with 13,830,508 votes for. An advisory resolution on executive compensation was approved with 10,970,705 votes for, and on a non-binding basis stockholders indicated a preference for holding future advisory votes on executive compensation every three years. The Board determined that future advisory say-on-pay votes will be held on a three-year schedule.
Ultralife Corporation reported a first-quarter 2026 net loss of $0.5 million, or ($0.03) per share, compared with net income of $1.9 million, or $0.11 per share, a year earlier. Revenue fell 6.5% to $47.4 million from $50.7 million, as Battery & Energy Products sales slipped to $44.2 million and Communications Systems sales dropped to $3.3 million.
Gross profit declined to $10.1 million, with gross margin compressing to 21.3% from , reflecting lost production days at Newark, NY and Raynham, MA facilities, higher utility costs and less favorable mix, along with weaker Communications Systems volume. Operating expenses rose to $10.3 million, including $0.8 million of non-recurring consulting and litigation costs.
Adjusted EBITDA was $3.2 million (6.8% of sales) versus $5.4 million (10.7% of sales) in the prior-year quarter. Despite the softer earnings, Ultralife’s order backlog reached a record $115.1 million, up from $95.0 million a year ago, supported by long-cycle orders for new products.
Ultralife Corporation reported fourth-quarter and full-year 2025 results showing solid revenue growth but a GAAP net loss driven by a non-cash brand write-down. Q4 revenue rose 10.6% to $48.5 million, led by 15.1% growth in Battery & Energy Products, while Communications Systems revenue fell 35.2% to $2.6 million on order timing.
Backlog increased to $110.2 million at year-end, up from $90.3 million in the prior quarter. Ultralife recorded a $12.2 million impairment on tradename and trademark intangibles tied to consolidating multiple acquired brands under the Ultralife master brand. This contributed to a Q4 net loss attributable to Ultralife of $7.4 million, or $(0.45) per share, compared with $0.2 million, or $0.01 per share, a year earlier.
Despite the impairment, adjusted EBITDA improved to $5.7 million in Q4 2025, or 11.7% of sales, versus $3.9 million or 8.9% a year ago, and reached $17.3 million on a trailing twelve‑month basis. Management highlighted operational restructuring, a unified brand strategy and strengthened plant leadership as steps intended to support profitable growth, cash generation and debt reduction in 2026.
Ultralife Corporation filed a current report to announce that it has released financial results for its third quarter ended September 30, 2025. The company states that these results are presented in a press release dated November 18, 2025, which is attached as Exhibit 99.1. The filing is signed by the Chief Financial Officer and Treasurer, highlighting that this is the formal disclosure of the latest quarterly performance details through the accompanying press release.
Ultralife Corporation replaced its independent auditor on August 22, 2025, when the Audit and Finance Committee approved ending the engagement with Freed Maxick P.C. and engaged Withum Smith+Brown, PC effective immediately due to Withum's acquisition of certain assets of Freed Maxick. Freed Maxick's audit reports for the years ended December 31, 2023 and December 31, 2024 contained no qualifications on the company’s financial statements, but its report on internal control over financial reporting for 2024 stated the company did not maintain effective internal control because of a material weakness. The company reported no disagreements or reportable events with Freed Maxick for the reviewed periods and furnished Freed Maxick a copy of this disclosure; Freed Maxick provided a letter dated August 25, 2025 responding to the disclosure.